This is an important daily activity to me to follow your information.
Featured in NEJM Journal Watch: Once-Weekly Therapy of Skin and Soft-Tissue Infections — Physician’s First Watch
Featured in NEJM Journal Watch: Once-Weekly Therapy of Skin and Soft-Tissue Infections
By the NEJM Journal Watch Editors
Both dalbavancin and oritavancin proved efficacious in clinical trials in the New England Journal of Medicine. In NEJM Journal Watch Infectious Diseases, Dr. Larry M. Baddour writes that adoption of these drugs "could dramatically change the outpatient management" of skin and soft-tissue infections.